## JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY, WAKNAGHAT

## TEST -3 EXAMINATION - 2025

B.Tech - VIII Semester (BT)

COURSE CODE (CREDITS): 18B1WBT833 (3)

MAX. MARKS: 35

COURSE NAME: DIAGNOSTICS AND VACCINE MANUFACTURE

COURSE INSTRUCTORS: Dr. Rahul Shrivastava

MAX. TIME; 2Hour

*Note:* (a) All questions are compulsory. (b) The candidate is allowed to make suitable numeric assumptions wherever required for solving problems

| Q. No         |  | Question   |  | CO                                       | Marks     |
|---------------|--|--|--|--|-----------|
| Q1            | A 2.9 Kb Thalassemi  | a diagnosis related gene needs to be ar                                      | unlified If there                        | Ι  |           |
|               | are four template DN   | A molecules present in the initial PCR i                                     | reaction mixture,                        |  | [1+1+2=4] |
|               | Calculate (and provi   | de reason) the number of molecules   | that would be                            |  |           |
|               | obtained after 5 cycles  | of PCR if the extension time used is:  |  |  |           |
|               | a. 1 min b.  | 2 mins c. 4 mins   |  |  |           |
|               | Forward and Reverse  | primers designed for amplification of  | of SigF gene of                          | I  |           |
|               | Mycobacterium tuberculosis show non-specific amplification, with the           |  |  |  | [5]       |
|               | homology search revealing binding of the forward and reverse primers at        |  |  |  |           |
|               | multiple locations in the genome. Design a strategy for specific amplification |  |  |  |           |
|               | of the gene, providing diagrams / flowchart.                                   |  |  |  |           |
| i.<br>a<br>ii | Antibiotic Susceptibility Test was performed using The Kirby-Bauer method      |  | V  | [1+2+2 = 5]                              |           |
|               | against pathogenic Salmonella bacteria. The test showed varied levels of       |  |  |  | •         |
|               | susceptibility. With reference to the table provided, answer the following     |  |  |  |           |
|               | questions:   |  | a la | an a |           |
|               | Antibiotic   | Used Diameter of the zone of inhibi  | tion                                     |  |           |
|               | Amikac   | n 12 cm  |  |  |           |
|               | Ciprofloxa   |  |  |  |           |
|               | Isoniazi   |  |  |  |           |
|               | Penicilli  | 10 011   |  |  |           |
|               | i. Compare and arrange   | . Compare and arrange the order of susceptibility of the Salmonella bacteria |  |  |           |
|               | against the antibiotics used, providing suitable reason for your order.        |  |  |  |           |
|               | i. Elaborate the method employed.  |  |  |  |           |
|               | ii. Discuss application of the assay in disease diagnostics and therapeutics.  |  |  |  |           |
|               |  | the ussay in usease diagnostics and th                                       | erapeutics.                              |  |           |

| Q4      | In a treatment strategy against pathogenic Multidrug-resistant Staphylococcus   | IV,  |                 |
|---------|---|------|-----------------|
| n hours | aureus, two different drugs (B & C) were tested by addition at early log stage  | V    | [1.5+1.5+2      |
|         | of the bacteria.  |      | 5]              |
|         | i. Compare the mode of inhibition of the two drugs <b>B</b> and <b>C</b> in comparison to the   |      |                 |
|         | control A (no drug) with  |      |                 |
|         | reason for your answer.   |      |                 |
|         | ii. Which drug do you think   |      | Car             |
|         | <ul> <li>ii. Which drug do you think<br/>should be administered<br/>for such MDR infections?</li> <li>iii. What are narrow and</li> </ul> | 100  | $(\Lambda^{*})$ |
|         | for such MDR infections?  |      |                 |
|         |   |      | n di<br>v       |
|         | broad spectrum  | 8 W. |                 |
|         | antibiotics? Differentiate  |      |                 |
|         | under what conditions   |      | (               |
|         | each must be used.  |      |                 |
| Q5      | Malaria is one of the oldest diseases known to mankind, yet no vaccine is   | III  |                 |
|         | available to tackle the disease.  | 111  |                 |
|         | A. Discuss the probable reasons why efforts towards vaccine development   |      |                 |
|         | against malaria have largely been unsuccessful.   |      | [2+2.5+2.5 =    |
|         | <b>B.</b> Illustrate the life cycle of a Malaria parasite.  |      | 7]              |
|         | C. Suggest important stages of the above life cycle which may be targeted for   |      |                 |
|         | vaccine intervention strategies and their significance.   |      |                 |
| Q6      | A person is suffering from or to for the  |      |                 |
|         | A person is suffering from an infection with symptoms of 'hydrophobia' and 'hallucinations'.  | III  | [2+2.5+2.5 =    |
|         |   |      | 7]              |
|         | by and pre and post exposure vaccines recommended for such  |      | C               |
|         | infections? Give details of such vaccines and their utility.  |      |                 |
|         | ii. Illustrate the transmission and pathogenesis of the infection.  |      |                 |
|         | iii. Provide details on Nerve Tissue and Cell Culture methods for   |      |                 |
| 4       | production of such vaccines.  |      |                 |
| 27      | Compare the advantages and limitations of delivery of a particulate antigen I   | II   | 2               |
| t       | through liposomes and microspheres  |      | 4               |